v3.25.4
Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements, Research and Development Arrangements and In-Licensing Arrangements - Pro Forma Information - Footnotes (Details) - Seagen [Member]
$ in Millions
 1 Months Ended
Dec. 31, 2023
USD ($)
Business Combination [Line Items]  
Net loss attributable to Pfizer Inc. common shareholders $ (746)
Restructuring, integration and acquisition-related costs [Member]  
Business Combination [Line Items]  
Net loss attributable to Pfizer Inc. common shareholders 614
Business Combination, Pro Forma Information, Nonrecurring Adjustment, Inventory, Fair Value Adjustment [Member]  
Business Combination [Line Items]  
Net loss attributable to Pfizer Inc. common shareholders 109
Amortization Expense [Member]  
Business Combination [Line Items]  
Net loss attributable to Pfizer Inc. common shareholders 25
Depreciation Expense [Member]  
Business Combination [Line Items]  
Net loss attributable to Pfizer Inc. common shareholders $ 2